Drug Trial Radar · NCT07169942
Aleniglipron Phase 2 Body Composition Study
Last checked: Nov 20, 2026Latest source record: Oct 14, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
71
Actual
Start
Aug 15, 2025
Primary completion
Sep 9, 2026
Study completion Sep 10, 2026
Sponsor
- Lead sponsor
- Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure TherapeuticsIndustry
- Sponsor type
- Industry
- First posted
- Sep 12, 2025
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, care provider, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 79 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a randomized, double-blind, placebo-controlled study evaluating the effects of aleniglipron on body composition in participants living with obesity. Participants will be randomized to aleniglipron or placebo in a ratio of 5:1. Participants will receive multiple ascending QD doses of aleniglipron or placebo in titration steps of 4 weeks duration for a total of 44 weeks of treatment.
Conditions
- Obesity, Overweight, or Chronic Weight Management
Interventions
aleniglipron or placeboDrug
Drug: aleniglipron administered orally Drug: placebo administered orally
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percent change in total body fat mass by DXATime frame: Baseline and week 44
Locations
11 sites in 1 country. Site status is shown where the registry gives one.
Research Site
Phoenix, Arizona
Research Site
Chicago, Illinois
Research Site
Richfield, Minnesota
Research Site
City of Saint Peters, Missouri
Research Site
Rochester, New York
Research Site
Wilmington, North Carolina
Research Site
Norman, Oklahoma
Research Site
Moncks Corner, South Carolina
Research Site
North Charleston, South Carolina
Research Site
Austin, Texas
Research Site
San Antonio, Texas
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.